Total Payments
$1.2M
2024 Payments
$24,670
Companies
84
Transactions
2,759
Medicare Patients
6,778
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$738,199 (63.7%)
Research$156,731 (13.5%)
Consulting$111,196 (9.6%)
Travel$99,390 (8.6%)
Food & Beverage$53,233 (4.6%)
Education$614.07 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $726,249 | 298 | 62.6% |
| Unspecified | $156,731 | 26 | 13.5% |
| Consulting Fee | $111,196 | 37 | 9.6% |
| Travel and Lodging | $99,390 | 455 | 8.6% |
| Food and Beverage | $53,233 | 1,920 | 4.6% |
| Honoraria | $11,950 | 8 | 1.0% |
| Education | $614.07 | 15 | 0.1% |
Payments by Type
General
$1.0M
2,733 transactions
Research
$156,731
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $656,766 | 741 | $0 (2024) |
| Genentech USA, Inc. | $116,384 | 178 | $0 (2024) |
| Biogen, Inc. | $96,320 | 270 | $0 (2024) |
| Horizon Therapeutics plc | $70,709 | 91 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $48,667 | 88 | $0 (2024) |
| EMD Serono, Inc. | $45,387 | 164 | $0 (2024) |
| ABBVIE INC. | $29,221 | 169 | $0 (2024) |
| Celgene Corporation | $27,030 | 56 | $0 (2024) |
| Allergan, Inc. | $14,119 | 78 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $12,673 | 235 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,670 | 197 | Genentech USA, Inc. ($8,847) |
| 2023 | $63,442 | 242 | Alexion Pharmaceuticals, Inc. ($12,076) |
| 2022 | $103,493 | 274 | Horizon Therapeutics plc ($39,578) |
| 2021 | $87,699 | 293 | Horizon Therapeutics plc ($20,539) |
| 2020 | $81,984 | 249 | GENZYME CORPORATION ($23,909) |
| 2019 | $318,998 | 500 | GENZYME CORPORATION ($241,282) |
| 2018 | $219,855 | 450 | GENZYME CORPORATION ($159,615) |
| 2017 | $259,223 | 554 | GENZYME CORPORATION ($198,965) |
All Payment Transactions
2,759 individual payment records from CMS Open Payments — Page 1 of 111
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 12/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Neuropsychiatry | ||||||
| 12/17/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: PAIN | ||||||
| 12/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.83 | General |
| Category: Neuroscience | ||||||
| 12/13/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $34.37 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.33 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $28.76 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: Neurology | ||||||
| 12/02/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $55.37 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $26.26 | General |
| 11/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $1.82 | General |
| Category: Neurology | ||||||
| 11/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $5.27 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Neuroscience | ||||||
| 11/19/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,537.00 | General |
| 11/19/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $123.60 | General |
| 11/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: PAIN | ||||||
| 11/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $3.37 | General |
| Category: Neurology | ||||||
| 11/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.63 | General |
| 11/14/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.26 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $26.18 | General |
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $3.10 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis | GENZYME CORPORATION | $117,812 | 2 |
| Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | GENZYME CORPORATION | $26,532 | 3 |
| A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis | SANOFI US SERVICES INC. | $7,302 | 4 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $2,476 | 10 |
| OCARINA I | F. Hoffmann-La Roche AG | $1,168 | 2 |
| A Prospective Observational Cohort Study in Adult Patients With Relapsing Multiple Sclerosis to Assess Patient Safety During and After LEMTRADA (alemtuzumab) Infusions of the First Treatment Course | GENZYME CORPORATION | $544.97 | 1 |
| A prospective observational cohort study in patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course | GENZYME CORPORATION | $352.63 | 1 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $313.33 | 1 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $130.00 | 1 |
| A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | GENZYME CORPORATION | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,750 | 25,135 | $1.1M | $372,064 |
| 2022 | 24 | 1,879 | 19,904 | $1.1M | $373,471 |
| 2021 | 22 | 1,836 | 20,098 | $1.1M | $383,956 |
| 2020 | 19 | 1,313 | 15,400 | $737,617 | $247,015 |
Total Patients
6,778
Total Services
80,537
Medicare Billing
$1.4M
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 661 | 1,310 | $222,700 | $119,403 | 53.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 43 | 22,600 | $248,600 | $111,389 | 44.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 257 | 257 | $81,212 | $40,428 | 49.8% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 71 | 71 | $40,683 | $23,082 | 56.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 124 | 126 | $212,184 | $16,028 | 7.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 169 | 213 | $82,005 | $15,385 | 18.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 99 | 107 | $25,787 | $14,010 | 54.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 33 | 88 | $26,400 | $10,627 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 68 | 76 | $8,512 | $4,872 | 57.2% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 36 | 36 | $45,468 | $3,163 | 7.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 65 | $17,160 | $3,130 | 18.2% |
| 92546 | Test for abnormal eye movement using a rotating chair | Office | 2023 | 31 | 31 | $5,146 | $2,961 | 57.5% |
| 92540 | Evaluation and testing for balance with recording | Office | 2023 | 31 | 31 | $10,106 | $2,599 | 25.7% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 15 | 15 | $31,575 | $2,350 | 7.4% |
| 92537 | Test to assess balance during warm and cool irrigation in both ears | Office | 2023 | 31 | 31 | $10,819 | $966.89 | 8.9% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 21 | 24 | $2,400 | $927.36 | 38.6% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 11 | 13 | $1,105 | $415.74 | 37.6% |
| 92547 | Use of electrodes during balance testing | Office | 2023 | 35 | 41 | $2,132 | $327.59 | 15.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 653 | 1,333 | $226,610 | $124,112 | 54.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 33 | 17,200 | $189,200 | $83,168 | 44.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 301 | 301 | $95,116 | $49,089 | 51.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 70 | 71 | $40,683 | $23,564 | 57.9% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 146 | 147 | $247,548 | $19,965 | 8.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 196 | 235 | $90,475 | $18,059 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 96 | 116 | $27,956 | $15,826 | 56.6% |
About Dr. Wm Honeycutt, M.D
Dr. Wm Honeycutt, M.D is a Specialist healthcare provider based in Maitland, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457340960.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wm Honeycutt, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $24,670 received in 2024. These payments were reported across 2,759 transactions from 84 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($726,249).
As a Medicare-enrolled provider, Honeycutt has provided services to 6,778 Medicare beneficiaries, totaling 80,537 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Maitland, FL
- Active Since 10/18/2005
- Last Updated 07/02/2010
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1457340960
Products in Payments
- AUBAGIO (Drug) $243,766
- LEMTRADA (Drug) $242,103
- SAR442168 (Drug) $133,966
- UPLIZNA (Drug) $70,709
- OCREVUS (Biological) $68,489
- UBRELVY (Drug) $36,581
- TYSABRI (Biological) $32,215
- Non-Covered Product (Drug) $30,934
- ZEPOSIA (Drug) $28,346
- TECFIDERA (Drug) $27,125
- Ocrevus (Biological) $21,981
- Mavenclad (Biological) $14,486
- ULTOMIRIS (Biological) $14,062
- VUMERITY (Drug) $11,406
- COPAXONE (Drug) $10,881
- Mavenclad (Drug) $7,668
- Ozanimod (Drug) $7,465
- AVONEX (Biological) $6,083
- Rebif (Biological) $5,856
- QULIPTA (Drug) $5,460
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Maitland
Dr. Arnaldo Isa, M.d, M.D
Specialist — Payments: $181,354
Specialist $181,354
Dr. Daniel Nieves-Quinones, M.d, M.D
Specialist — Payments: $40,942
Specialist $40,942
Thomas Blake, Md, MD
Specialist — Payments: $1,847
Specialist $1,847
Dr. Boris Coronado, Md, MD
Specialist — Payments: $543.60
Specialist $543.60
Kelly Verbal, Arnp, Crna, ARNP, CRNA
Specialist — Payments: $121.73
Specialist $121.73
David Simmons, M.d, M.D
Specialist — Payments: $103.94
Specialist $103.94